Advanced Proteome Therapeutics Performance
| APTCFDelisted Stock | USD 0.0002 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Advanced Proteome are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Advanced Proteome Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable fundamental indicators, Advanced Proteome is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 822.4 K | |
| Total Cashflows From Investing Activities | -13.8 K |
Advanced |
Advanced Proteome Relative Risk vs. Return Landscape
If you would invest 0.02 in Advanced Proteome Therapeutics on November 8, 2025 and sell it today you would earn a total of 0.00 from holding Advanced Proteome Therapeutics or generate 0.0% return on investment over 90 days. Advanced Proteome Therapeutics is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Advanced, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Advanced Proteome Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Advanced Proteome for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Advanced Proteome can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Advanced Proteome is not yet fully synchronised with the market data | |
| Advanced Proteome has some characteristics of a very speculative penny stock | |
| Advanced Proteome has a very high chance of going through financial distress in the upcoming years | |
| Advanced Proteome Therapeutics has accumulated 227.41 K in total debt with debt to equity ratio (D/E) of 4.65, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Advanced Proteome has a current ratio of 0.54, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Advanced Proteome until it has trouble settling it off, either with new capital or with free cash flow. So, Advanced Proteome's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Advanced Proteome sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Advanced to invest in growth at high rates of return. When we think about Advanced Proteome's use of debt, we should always consider it together with cash and equity. | |
| Advanced Proteome Therapeutics has accumulated about 761.6 K in cash with (693.58 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Advanced Proteome Fundamentals Growth
Advanced Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Advanced Proteome, and Advanced Proteome fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Advanced Pink Sheet performance.
| Return On Asset | -1.07 | |||
| Current Valuation | 660.53 K | |||
| Shares Outstanding | 41.13 M | |||
| Price To Earning | 2.98 X | |||
| Price To Book | 4.92 X | |||
| EBITDA | 631.22 K | |||
| Cash And Equivalents | 761.6 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 227.41 K | |||
| Debt To Equity | 4.65 % | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (693.58 K) | |||
| Earnings Per Share | 0.02 X | |||
| Total Asset | 636.41 K | |||
About Advanced Proteome Performance
By analyzing Advanced Proteome's fundamental ratios, stakeholders can gain valuable insights into Advanced Proteome's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Advanced Proteome has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Advanced Proteome has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and immunomodulation. Advanced Proteome operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Advanced Proteome performance evaluation
Checking the ongoing alerts about Advanced Proteome for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Advanced Proteome help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Advanced Proteome is not yet fully synchronised with the market data | |
| Advanced Proteome has some characteristics of a very speculative penny stock | |
| Advanced Proteome has a very high chance of going through financial distress in the upcoming years | |
| Advanced Proteome Therapeutics has accumulated 227.41 K in total debt with debt to equity ratio (D/E) of 4.65, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Advanced Proteome has a current ratio of 0.54, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Advanced Proteome until it has trouble settling it off, either with new capital or with free cash flow. So, Advanced Proteome's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Advanced Proteome sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Advanced to invest in growth at high rates of return. When we think about Advanced Proteome's use of debt, we should always consider it together with cash and equity. | |
| Advanced Proteome Therapeutics has accumulated about 761.6 K in cash with (693.58 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Advanced Proteome's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Advanced Proteome's stock is overvalued or undervalued compared to its peers.
- Examining Advanced Proteome's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Advanced Proteome's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Advanced Proteome's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Advanced Proteome's pink sheet. These opinions can provide insight into Advanced Proteome's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Advanced Pink Sheet
If you are still planning to invest in Advanced Proteome check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Advanced Proteome's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |